July 26, 2022, Tokyo, Japan – PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel synthetic peptide “BMP4,7 inhibitor (Noggin-like peptide)” which binds to several Bone Morphogenetic Proteins (BMPs) to inhibit its activity like Noggin. It will be marketing this product from July, 2022.
Development of Synthetic Peptide Growth Factors by PeptiGrowth
Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products are facing various challenges such as lot-to-lot quality variations, potential contamination with biological impurities, low stability, and high cost. PeptiGrowth has been working on the development of a series of synthetic peptides that have the same functions as conventional growth factors and cytokines, and that can address and solve all these challenges. Its peptides are completely chemically synthesized and animal component-free.
About BMP4,7 inhibitor (Noggin-like peptide) [Product code: PG-004]
Inhibitory activity against BMP4 and BMP7
PeptiGrowth performed a functional comparison test between its Noggin-like peptide and commercially available recombinant Noggin. From the results, PeptiGrowth’s Noggin-like peptide showed the inhibitory activity against BMP4 and BMP7 at the same level per molecule compared with recombinant Noggin. PeptiGrowth also confirmed that its Noggin-like peptide exhibits the inhibitory activity against BMP family proteins with high sequence homology to BMP4 and BMP7. The molecular weight (MW) of its Noggin-like peptide is approximately 2.9 kDa, which is about 8 times smaller than the MW of recombinant Noggin.
PeptiGrowth’s Noggin-like peptide is expected to be used to maintain undifferentiation and induce differentiation in the development and manufacture of regenerative medicine and cell therapy for pancreas, lung, intestine, etc., which have been actively researched and developed in recent years, and in the preparation of organoids.
Product Overview
Product name: BMP4,7 inhibitor (Noggin-like peptide)
Product Code: PG-004
Product form: Lyophilized
Storage conditions: -20 °C or less
Purity: ≥95% by HPLC
Molecular weight: 2920.15
Size: 5 μg (volume per a glass vial)
*This product can be provided Animal Component Free (ACF) certificate.
*This product is for testing and research use only (RUO).
*There is a possibility that the specification would be changed.
Development of Inhibitory Peptides Specific to BMP4 or BMP7
In addition to the newly released Noggin-like peptide, PeptiGrowth is also developing peptides that specifically inhibit BMP4 or BMP7. It is expected to be used for detailed analysis of BMP signals in cell development.
If you would like to purchase, please contact PeptiGrowth’s agent in North America, Mitsubishi International Food Ingredients, Inc., at FineChem@mitsubishiingredients.com or +1 (201) 681-1268.
PeptiGrowth can also discuss the supply of GMP-grade products for bulk consumption.
Development of other peptides from PeptiGrowth
PeptiGrowth was established in April 2020 as a joint venture between Mitsubishi Corporation and PeptiDream Inc. with the mission to address various challenges that regenerative medicine and cell therapy industry is facing and to contribute to its growth. Following HGF Alternative Peptide, TGFβ1 inhibitor, BDNF alternative peptide, and Noggin-like peptide, PeptiGrowth is planning to launch the next product by the end of September 2022. Details will be updated on its website upon release.
Source: PeptiGrowth